Physician

Chang O Son, M.D.

According to 2025 Medicare claims, Chang Son, M.D. (NPI: 1396016838) practices medical oncology in the Fayetteville, NC market, with the plurality of this provider's patient population coming from Cumberland, NC. This provider's primary affiliated billing organization is CUMBERLAND COUNTY HOSPITAL SYSTEM INC (NPI: 1245661701; TIN: 560845796) and primary practice location at 28311-9442. Son is affiliated with the Coastal Plains Network, LLC (ACO ID: A2684), AdvantagePoint Health Alliance - Blue Ridge, LLC (ACO ID: A4654), CoreHealth Alliance LLC (ACO ID: A5645), and PeaceHealth Direct Contracting LLC (ACO ID: D0152), participating under both the MSSP and REACH models.

Son's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 165 traditional Medicare patients, billed 285 HCPCS/CPT codes, and received $20,477 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 325 prescription claims across 94 beneficiaries totaling $1,372,355 in drug costs, led by Imbruvica (Ibrutinib). 2022 DME data shows 12 claims. Open Payments data shows 22 records totaling $479. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $25,657 and ending at $20,477. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $433,366 to $1,372,355. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	266	564	$25,657
2019	326	759	$38,776
2020	296	652	$30,985
2021	262	696	$39,322
2022	246	521	$28,743
2023	118	244	$15,094
2024	165	285	$20,477

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	563	5,475	$433,366
2016	498	4,489	$665,571
2017	453	3,343	$829,351
2018	153	595	$802,259
2019	107	398	$691,287
2020	115	397	$687,875
2021	118	464	$971,618
2022	126	586	$1,456,062
2023	64	182	$844,788
2024	94	325	$1,372,355

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	12	$164
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	22	22	$102
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	72	93	$72
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	24	24	$60
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	29	36	$53
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	28	43	$26

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	19	536	$290,072
Xtandi	Enzalutamide	15	450	$209,685
Tasigna	Nilotinib Hcl	13	364	$207,065
Ninlaro	Ixazomib Citrate	16	448	$203,432
Eliquis	Apixaban	51	1,890	$36,977

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	22	$479	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chang O. Son, M.D.?

Tedicare shows public-source Medicare data for Chang O. Son, M.D. (NPI 1396016838), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chang O. Son, M.D. have ACO affiliation data?

Chang O. Son, M.D. is shown with ACO affiliation data for Coastal Plains Network, LLC (MSSP, ACO ID A2684), AdvantagePoint Health Alliance - Blue Ridge, LLC (MSSP, ACO ID A4654), CoreHealth Alliance LLC (MSSP, ACO ID A5645), and PeaceHealth Direct Contracting LLC (REACH, ACO ID D0152).

What billing organization is linked to Chang O. Son, M.D.?

Chang O. Son, M.D. is linked to CUMBERLAND COUNTY HOSPITAL SYSTEM INC (billing NPI 1245661701) in the available physician profile data.

Does Chang O. Son, M.D. have Open Payments data?

Chang O. Son, M.D. has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.